 |
Affymetrix Launches Industry's Broadest-Selection of Standard and Custom SNP PanPosted by admininvest on: 2005-12-20 10:04:26
Affymetrix Launches Industry's Broadest-Selection of Standard and Custom SNP Panels for Targeted Genotyping Applications; Highly Multiplexed Assays Provide Data On 1,500 to 20,000 Selected SNPs SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec. 19, 2005--Affymetrix Inc. (Nasdaq:AFFX) today launched the industry's broadest-selection of standard and custom SNP panels for targeted genotyping applications. The new selection includes custom panels spanning 1,500 to 20,000 SNPs per assay, as well as seven standard SNP panels for whole-genome coding SNP analysis, disease-related studies and common animal research. These new SNP panels use the latest generation of highly multiplexed Molecular Inversion Probe (MIP) assay technology, giving scientists more SNP data per experiment. The new GeneChip(R) Application-Specific Fixed Assay panels include: -- Whole-genome: 20K cSNP, 10K cSNP, 3K MALD (Mapping by Admixture Linkage Disequilibrium) -- Disease-related candidate gene: 9K Immune-Inflammation Panel -- Animal model: 10K Bovine, 5K Mouse, 5K Rat "We have used an Affymetrix custom SNP panel for a study on obesity," said Michael Olivier, associate professor of physiology at the Medical College of Wisconsin. "The MIP assay technology is very easy-to-use and has enabled us to complete a 1,600-sample study in less than two months with very high call rates." The new assays are the first MIP products to be released since Affymetrix acquired ParAllele BioScience in October 2005. They are based on the same assay (formerly marketed as MegAllele) that was used successfully in the International Human Haplotype Mapping (HapMap) Project. The highly multiplexed assay technology enables individual researchers to benefit more than ever from the HapMap by cost-effectively genotyping more SNPs in their experiments. Researchers can use standard fixed assays or select custom panels ranging from 1,500 to 20,000 SNPs. "Affymetrix is providing customers with the most multiplexed, highest information per dollar assays for genotyping selected SNPs," said Greg Yap, vice president of DNA Products at Affymetrix. "When combined with our existing products such as the GeneChip Mapping 500K Set, our portfolio of products helps customers make better discoveries faster. Affymetrix is accelerating the development and commercialization of new products that are enabling researchers to conduct large-scale studies to find the genes involved in complex diseases." Applications Discovering Disease Genes Through Whole-genome Association Analysis In conjunction with the GeneChip Human Mapping 500K Array Set, researchers can either use the 20K cSNP Kit to look at 20,000 coding SNPs or design custom SNP panels to analyze regions of interest in greater detail. These studies will yield many regions and SNPs worthy of further investigation. Researchers can also use custom panels of up to 20,000 SNPs to follow up on these experiments. Disease-related Candidate Gene Studies Researchers studying the genetics of immunobiology can use the Affymetrix GeneChip Human Immune and Inflammation 9K SNP Kit, which contains selected informative markers for 1,000 genes that are thought to be involved in the inflammation response. This panel lets researchers study all of the emerging candidate genes or regions potentially involved in a given immunological condition, not just a few hundred or thousand SNPs. Common Animal Research Standard Affymetrix GeneChip SNP panels for various animal species enable researchers to perform unbiased gene mapping studies on different breeds or strains of cows, mice and rats. These kits are multiplexed in a single assay and offer researchers the first SNP-based products for these mapping applications. These new multiplexed panels are designed for use with the GeneChip Scanner 3000 Targeted Genotyping System. For more information on Affymetrix' targeted genotyping solutions, please visit the company's Web site at: http://www.affymetrix.com/products/application/ targeted_genotyping.affx (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) Affymetrix will introduce new standard SNP panels for applications that include cancer, cardiovascular disease and other important medical conditions over the next few months. About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,300 systems have been installed around the world and nearly 3,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif. with subsidiaries in Europe and Asia, as well as manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 1,000 employees worldwide. For more information about Affymetrix, please visit the company's Web site at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing (including risks related to the Company's ability to achieve hoped-for manufacturing yields for certain array products, including the ability to identify and resolve manufacturing problems), product development (including uncertainties relating to commercial and technological success of the standard and custom SNP panels for targeted genotyping applications discussed in this press release); personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2004, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip are registered trademarks owned or used by Affymetrix Inc. Contacts Affymetrix Inc. Wes Conard, 408-731-5791 (Media) Doug Farrell, 408-731-5285 (Investor Relations) At A Glance Affymetrix, Inc. Headquarters: Santa Clara, California Website: http://www.affymetrix.com CEO: Stephen Fodor Employees: 900 Ticker: AFFX (NASDAQ) Revenues: $346M (2004) Net Income: $48M (2004) Source: via Business Wire Updated 09/06/2005 by company Open community website http://www.business-business.biz http://www.investment-investment.us http://www.retirement-retirement.com Recommended sites Open community website http://www.business-business.biz http://www.investment-investment.us http://www.retirement-retirement.com Recommended sites To design your custom retirement plan. http://www.retirement-plan.us For planning an IRA rollover this is the site to review. http://www.ira-rollover.us For professional asset allocation and the wonders it can do. http://www.asset-allocation.us Managers selected to fit your needs. http://www.money-managers.us |
|
Related Stories Affymetrix Fourth Quarter and YearAffymetrix entered collaboration with Duke UniversityAffymetrix: Three stumbles then a step? |
|
Post new CommentThis site does not allow anonymous comments. Registered members can login to participate. Registration is free and takes only a few seconds |
|